Blue Cross NC Adds New Biosimilars for Humira (adalimumab) to Commercial Formularies
On 7/1/2023, new biosimilars for Humira (adalimumab) will be added to Blue Cross and Blue Shield of North Carolina commercial formularies. There will be no changes in coverage of Humira products. Coverage of specific biosimilars will vary by formulary, but may include Amjevita, Cyltezo, or Hadlima. You can identify preferred products on MyPrime.com after 7/1/2023. Because there are no clinically meaningful differences between Humira and the biosimilar adalimumab products, patients are not expected to experience a change in the safety or effectiveness of their treatment if members utilize covered adalimumab biosimilars. Refer to the FDA resource (PDF) for further information.
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.